Neuronetics (NASDAQ: STIM) is one of 121 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Neuronetics to related companies based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, risk, valuation and earnings.
This is a summary of recent recommendations and price targets for Neuronetics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Neuronetics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
68.7% of Neuronetics shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 12.0% of Neuronetics shares are owned by insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Neuronetics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Neuronetics||$52.78 million||-$24.10 million||-5.78|
|Neuronetics Competitors||$1.48 billion||$146.48 million||39.08|
Neuronetics’ rivals have higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Neuronetics beats its rivals on 7 of the 12 factors compared.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.